Humana's (HUM) Q4 results have left many investors with "questions around just how long the Stars turnaround will take outside of the ongoing [payment year 2026] litigation," Morgan Stanley said in a note to clients on Wednesday.
The investment firm highlighted the fact that there was "no color on when Stars litigation outcome is expected."
In October, Humana started legal action against the US Department of Health and Human Services and the Centers for Medicare and Medicaid Services over the 2025 Medicare Advantage's Star Ratings assigned to its plans, according to media reports.
"The Stars overhang remains a key swing factor in [Humana's] timeline to achieve target [Medicare Advantage] margins," Morgan Stanley said in the note.
The investment firm said it's reiterating "prior assumptions on the potential Stars headwind in 2026, which could amount to an unmitigated -126% headwind to EPS."
Morgan Stanley cut Humana's price target to $285 from $301 and kept the company's equal-weight rating, citing "persistent uncertainty."
Price: 265.99, Change: +8.65, Percent Change: +3.36
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。